EP Study of Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound (AfMAZE EP)

September 18, 2017 updated by: University Hospital Plymouth NHS Trust

EP Study at >1 Year to Evaluate the Presence of Conduction Block Across the Cinch Line in Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound(HIFU)

The purpose of this study is to check if at 1 year after surgical ablation the electrical impulses that cause atrial fibrillation (AF) are still blocked from being able to get into the heart.

Hypothesis Conduction block and ganglionic destruction are required for freedom from AF.

Study Overview

Status

Completed

Conditions

Detailed Description

Atrial fibrillation (AF) is an increasing common disease. It ranges from being asymptomatic to a highly disabling condition with a severe impact on quality of life. It is termed paroxysmal (PAF) when an episode lasts less than 7 days, persistent (PerAF) when it lasts more than 7 days and needs intervention and permanent (PermAF) when it is accepted as the long term rhythm. Treatment is based on symptom control and the prevention of complications such as stroke. When an attempt is made to restore normal sinus rhythm (NSR), this is termed 'rhythm control'.

Treatments for rhythm control of AF can be broadly divided into pharmacological and ablative. Ablative techniques1 are typically performed percutaneously using catheter-based technology (minimally invasive), though some surgical techniques also exist. They work on the principle that performing a series of 'burns' (scar) in appropriate places can prevent abnormal electrical signals forming and propagating within the heart.

The problem of atrial fibrillation is vast. Prevalence ranges from 0.2% in the 45-54 age group, rising to 8% in the over 75s. Though the majority of patients can be satisfactorily treated medically, in a not insignificant portion, the drugs are either poorly tolerated or are ineffective. For these patients, the United Kingdom (UK) NICE guidelines recommend consideration of an ablation procedure. In Derriford hospital alone we see approximately 14 patients suitable for AF ablation in a typical month.

The electrophysiological consequences of ablation are unclear. It is not known whether complete bidirectional electrical block across the ablation lines isolating the pulmonary antral region from the rest of the left atrium is a prerequisite for long-term cure of Atrial Fibrillation (AF). Studies in canine models of atrial fibrillation have suggested that incomplete lines of block can be as effective in reducing AF burden as complete lines, however the limited number of follow up studies in humans that have assessed both patients with recurrent AF and also asymptomatic patients who appear to have been cured by catheter ablation have suggested that complete electrical isolation of the pulmonary veins is necessary for a cure. Advocates for ablation without assessing electrical block argue success rates in humans are similar whether circumferential electrical isolation of the pulmonary veins is achieved or not. Assessing freedom from AF and correlating it with the presence or absence of complete bidirectional electrical block, intra-operatively and at post one-year follow-up, will allow a further understanding of the mechanisms determining the success or failure of AF ablation therapies. This will be very important in knowing how to treat patients in whom AF still occurs and will guide the approach to subsequent interventions.

Though there is a small risk involved in this study, the question it addresses will have a significant impact on the development of future AF ablation techniques. Within this group, over 300 separate ablation procedures have been performed with no deaths or significant complications. Previous groups have published trans-septal observational studies in humans demonstrating that previous ethics committees have appreciated the importance of such work. The 2012 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) consensus statement on catheter and surgical ablation for AF has recently highlighted the need for novel trial designs demonstrating 'durability of pulmonary vein isolation' with a repeat diagnostic electrophysiological study.

This trial will therefore increase our understanding of the electrophysiological properties associated with successful ablation and how Atrial Fibrillation ablation and the HIFU procedure work.

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Devon
      • Plymouth, Devon, United Kingdom, PL6 8BX
        • Plymouth Hosptals NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Secondary care clinic - Patients who have undergone an Epicor HIFU ablation >12 months ago

Description

Inclusion Criteria:

  • All patients will be screened prior to enrollment in the study. The following inclusion criteria will apply to all prospective candidates:

    • Patients who have undergone an Epicor HIFU ablation >12 months ago
    • Patients having the ability to fully comply with the study requirements
    • Patients who have given written fully informed consent to participate in the study

Exclusion Criteria:

  • Patients will be excluded from the study if they meet any of the following criteria:

    • Patients who are unable to give full informed consent for the present sub-study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Surgical operation
The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To document the incidence of 1 year post ablation bidirectional conduction block through the pulmonary venous cinch and mitral lines
Time Frame: 1 year
Incidence of conduction block post ablation at 12 months across the pulmonary venous and mitral lines.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Malcolm Dalrymple-Hay, MB BS, PhD, University Hospital Plymouth NHS Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Actual)

September 1, 2013

Study Completion (Actual)

September 1, 2013

Study Registration Dates

First Submitted

November 1, 2012

First Submitted That Met QC Criteria

January 14, 2013

First Posted (Estimate)

January 16, 2013

Study Record Updates

Last Update Posted (Actual)

September 19, 2017

Last Update Submitted That Met QC Criteria

September 18, 2017

Last Verified

September 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

3
Subscribe